# Boston Scientific Corporation (BSX)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $72.24B  
**Price:** $48.34 (-1.27%)

> Boston Scientific Corporation develops, manufactures, and markets a broad portfolio of medical devices designed for minimally invasive procedures worldwide. The company specializes in innovative technologies that address critical health needs across cardiology, endoscopy, and neuromodulation. Its Cardiovascular segment offers products for angioplasty, stents, cardiac rhythm management, and structural heart interventions, while the MedSurg segment provides solutions for endoscopy, urology, neuromodulation for chronic pain, interventional oncology, and treatments for incontinence and kidney stones. These devices enable healthcare professionals to perform precise diagnostics and therapies with reduced patient recovery times. Boston Scientific Corporation serves physicians, hospitals, and healthcare institutions globally, with a significant portion of sales from international markets. Founded in 1979 and headquartered in Marlborough, Massachusetts, it plays a vital role in advancing interventional medicine and improving patient outcomes in high-volume therapeutic areas.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $20.07B | $13.85B | $3.61B | — | — |
| 2024 | $16.75B | $11.49B | $2.60B | — | — |
| 2023 | $14.24B | $9.90B | $2.34B | — | — |
| 2022 | $12.68B | $8.73B | $1.65B | — | — |
| 2021 | $11.89B | $8.18B | $1.20B | — | — |
| 2020 | $9.91B | $6.45B | -$80M | — | — |
| 2019 | $10.73B | $7.62B | $1.52B | — | — |
| 2018 | $9.82B | $7.01B | $1.51B | — | — |
| 2017 | $9.05B | $6.46B | $1.28B | — | — |
| 2016 | $8.39B | $5.96B | $447M | — | — |
| 2015 | $8.07B | $5.30B | -$283M | — | — |
| 2014 | $7.46B | $5.17B | -$301M | — | — |
| 2013 | $7.07B | $4.97B | $120M | — | — |
| 2012 | $6.96B | $4.90B | -$3.87B | — | — |
| 2011 | $7.62B | $4.96B | $904M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $43.67B | $19.44B | $24.23B | $1.97B | — |
| 2024 | $39.40B | $17.63B | $21.77B | $414M | — |
| 2023 | $35.14B | $15.85B | $19.28B | $865M | — |
| 2022 | $32.47B | $14.90B | $17.57B | $928M | — |
| 2021 | $32.23B | $15.61B | $16.62B | $1.93B | — |
| 2020 | $30.78B | $15.45B | $15.33B | $1.73B | — |
| 2019 | $30.57B | $16.69B | $13.88B | $217M | — |
| 2018 | $21.00B | $12.27B | $8.73B | $146M | — |
| 2017 | $19.04B | $12.03B | $7.01B | $188M | $3.81B |
| 2016 | $18.10B | $11.36B | $6.73B | $196M | $5.42B |
| 2015 | $18.13B | $11.81B | $6.32B | $319M | $5.65B |
| 2014 | $17.02B | $10.57B | $6.46B | $587M | $4.20B |
| 2013 | $16.57B | $10.03B | $6.54B | $217M | $4.20B |
| 2012 | $17.15B | $10.28B | $6.87B | $207M | $4.20B |
| 2011 | $21.29B | $9.94B | $11.35B | $267M | $4.20B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $4.53B | $876M | $3.66B |
| 2024 | $3.44B | $790M | $2.65B |
| 2023 | $2.50B | $711M | $1.79B |
| 2022 | $1.53B | $588M | $938M |
| 2021 | $1.87B | $554M | $1.32B |
| 2020 | $1.51B | $376M | $1.13B |
| 2019 | $1.84B | $461M | $1.38B |
| 2018 | $310M | $316M | -$6M |
| 2017 | $1.43B | $319M | $1.11B |
| 2016 | $1.18B | $376M | $806M |
| 2015 | $691M | $247M | $444M |
| 2014 | $1.27B | $259M | $1.01B |
| 2013 | $1.11B | $245M | $865M |
| 2012 | $1.28B | $226M | $1.05B |
| 2011 | $1.01B | $304M | $704M |

Source: [CompaniesByCap](https://companiesbycap.com/company/BSX)